LYGEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LYGEN (LYGEN).
Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.
| Metabolism | Primarily hepatic via CYP450 enzymes, including CYP3A4 and CYP2D6; undergoes N-demethylation, N-deethylation, and hydroxylation. |
| Excretion | Renal (90% as unchanged drug), biliary/fecal (10%) |
| Half-life | 12 hours; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min) |
| Protein binding | 85% bound to albumin |
| Volume of Distribution | 1.5 L/kg (reflects extensive tissue distribution) |
| Bioavailability | Oral: 70-80% (first-pass metabolism reduces from 90% intrinsic absorption) |
| Onset of Action | Intravenous: 5-10 minutes; Oral: 30-60 minutes |
| Duration of Action | 6-8 hours for intravenous; 12 hours for oral dosing |
| Molecular Weight | 378.46 |
For adults, administer 500 mg orally twice daily with or without food.
| Dosage form | CAPSULE |
| Renal impairment | For GFR 30-89 mL/min: 500 mg orally once daily. For GFR <30 mL/min or on hemodialysis: 250 mg orally once daily. Administer after dialysis on dialysis days. |
| Liver impairment | Child-Pugh A and B: No adjustment necessary. Child-Pugh C: Contraindicated; do not use. |
| Pediatric use | For children 2-12 years: 10 mg/kg orally twice daily; maximum 500 mg per dose. For children 12-18 years: Administer as adult dose. |
| Geriatric use | Initiate at 250 mg orally twice daily for patients ≥65 years. Titrate to 500 mg twice daily as tolerated. Monitor renal function closely. |
| 1st trimester | No adequate studies in pregnant women; avoid unless benefit outweighs risk. |
| 2nd trimester | Use only if clearly needed; potential fetal risk. |
| 3rd trimester | Avoid due to possible adverse neonatal effects. |
Clinical note
Comprehensive clinical and safety monograph for LYGEN (LYGEN).
| Placental transfer | Crosses placenta in animal studies; unknown in humans. |
| Breastfeeding | Excreted in human milk; discontinue nursing or drug, considering importance to mother. |
| Lactation Rating | L4 |
■ FDA Black Box Warning
Not applicable; no FDA-approved indications and no FDA boxed warnings exist for LSD.
| Serious Effects |
Hypersensitivity to LYGENSevere hepatic impairmentConcurrent MAOI therapy
| Precautions | Risk of severe psychological distress, prolonged psychosis, hallucinogen persisting perception disorder (HPPD), and suicide., May exacerbate psychiatric conditions; use only under strict medical supervision in research settings., Potential for serotonin syndrome when combined with serotonergic drugs. |
| Food/Dietary | No specific food interactions are documented for LYGEN. It can be taken with or without food. However, grapefruit juice may theoretically affect CYP3A4 metabolism, but clinical significance is minimal. Alcohol should be avoided due to additive CNS depression. |
Loading safety data…
| Teratogenic Risk |
| No human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: avoid unless benefit outweighs risk; second/third trimester: limited data, use caution. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and fetal growth via ultrasound; assess for signs of fetal distress in third trimester. |
| Fertility Effects | Preclinical studies indicate reversible impairment of spermatogenesis in males; no data on female fertility; advise patients of potential impact on reproductive capacity. |
| Clinical Pearls | LYGEN (lacosamide) is a third-generation antiepileptic drug that selectively enhances slow inactivation of voltage-gated sodium channels. Key pearls: 1) Titrate slowly (50 mg BID weekly) to minimize CNS side effects like dizziness and ataxia. 2) Dose adjustment needed for CrCl <30 mL/min (max 300 mg/day). 3) Can cause PR interval prolongation; avoid in patients with second- or third-degree AV block. 4) Contraindicated in severe hepatic impairment (Child-Pugh C). 5) Available as oral tablets, oral solution, and IV; IV to oral conversion 1:1. |
| Patient Advice | Take LYGEN exactly as prescribed; do not suddenly stop taking it without talking to your doctor, as this can increase seizure frequency. · You may experience dizziness or blurred vision, especially at the start of treatment; avoid driving or operating heavy machinery until you know how the medication affects you. · LYGEN can cause a slow heart rate or fainting; tell your doctor if you have a history of heart problems or if you feel your heart beating slowly or irregularly. · Do not drink alcohol while taking LYGEN, as it may worsen side effects like drowsiness and dizziness. · If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits with your doctor. |